Cancer
Survivin 95-104 (HLA-A*02:01) ELTLGEFLKL
Product number: EP07873_5
€210.00*
Prices excl. VAT plus shipping
costs
Available, delivery time:
1-3 days
sterile and endotoxin free
Delivery Format: The product is supplied freeze dried.
Purity:
95% HPLC-MS
Caution:
For research use only. Not for use in humans.
Amount in mg
1
Description
Survivin-derived peptide of ELTLGEFLKL sequence covering 95ï¾–104 and A*02:01 molecule.Single peptide (ELTLGEFLKL) for stimulation of human Survivin -specific CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-A*02:01 allele. Antigen Peptide Survivin HLA-A*02:01 (ELTLGEFLKL) for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxity or proliferation assays.
TechData
| Sequence: | ELTLGEFLKL |
| Delivery: | 1-3 days |
| C-Terminus: | OH |
| N-Terminus: | H |
| Amount: | 5 mg |
| Counterion: | TFA |
| Protein: | Survivin |
| Species: | Human |
| Allele: | HLA-A*02:01 |
| Application: | T-cell assays, Immune monitoring, Antigen specific T-cell stimulation, T-cell expansion, Cellular immune response |
| Indication: | Cancer |
| Purity: | 95% HPLC-MS |